11月18日 - ** 制药商旺达制药VNDA.O股价盘前上涨7%至4.71美元
** 该公司称，根据一项新的临床试验结果，其试验性药物替替匹坦（tradipitant）可显著减轻服用流行减肥药Wegovy的患者的恶心和呕吐症状。
** 研究达到了主要目标，29.3%的人服用了替替匹坦而58.6%的人服用了安慰剂；还减少了严重的恶心 - VNDA
** 公司称计划于 2026 年进行后期试验
** 全球GLP-1市场规模超过500亿美元；替替匹坦可提高依从性 - VNDA
** 截至最后收盘，该股今年累计下跌约 8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.